{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:40:36Z","timestamp":1772923236653,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s10147-019-01412-2","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T05:17:33Z","timestamp":1549689453000},"page":"842-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Hideaki","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"1412_CR1","doi-asserted-by":"publisher","first-page":"R305","DOI":"10.1677\/ERC-10-0187","volume":"17","author":"N Sharifi","year":"2010","unstructured":"Sharifi N, Gulley JL, Dahut WL (2010) An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17:R305\u2013R315","journal-title":"Endocr Relat Cancer"},{"key":"1412_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","volume":"50","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, Bellmunt J, Fizazi K et al (2014) Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50:1617\u20131627","journal-title":"Eur J Cancer"},{"key":"1412_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00345-016-1803-9","volume":"34","author":"F Rozet","year":"2016","unstructured":"Rozet F, Roumegu\u00e8re T, Spahn M et al (2016) Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol 34:1505\u20131513","journal-title":"World J Urol"},{"key":"1412_CR4","first-page":"336","volume":"30","author":"J Luo","year":"2016","unstructured":"Luo J, Beer TM, Graff JN (2016) Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 30:336\u2013344","journal-title":"Oncology"},{"key":"1412_CR5","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800\u20133806","journal-title":"J Clin Oncol"},{"key":"1412_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","volume":"96","author":"DM Moreira","year":"2016","unstructured":"Moreira DM, Howard LE, Sourbeer KN et al (2016) Predictors of time to metastasis in castration-resistant prostate cancer. Urology 96:171\u2013176","journal-title":"Urology"},{"key":"1412_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408\u20131418","journal-title":"N Engl J Med"},{"key":"1412_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465\u20132474","journal-title":"N Engl J Med"},{"key":"1412_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.juro.2018.03.125","volume":"200","author":"CJ Ryan","year":"2018","unstructured":"Ryan CJ, Crawford ED, Shore ND et al (2018) The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer. J Urol 200:344\u2013352","journal-title":"J Urol"},{"key":"1412_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/iju.13372","volume":"24","author":"A Mizokami","year":"2017","unstructured":"Mizokami A, Kadono Y, Kitagawa Y et al (2017) Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Int J Urol 24:566\u2013572","journal-title":"Int J Urol"},{"key":"1412_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"1412_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3892\/mco.2016.817","volume":"4","author":"H Momozono","year":"2016","unstructured":"Momozono H, Miyake H, Tei H et al (2016) Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. Mol Clin Oncol 4:839\u2013844","journal-title":"Mol Clin Oncol"},{"key":"1412_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152\u2013160","journal-title":"Lancet Oncol"},{"key":"1412_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"1412_CR15","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R et al (2016) Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol 34:2098\u20132106","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"1412_CR16","doi-asserted-by":"publisher","first-page":"55S","DOI":"10.2967\/jnumed.115.169730","volume":"57","author":"M Beheshti","year":"2016","unstructured":"Beheshti M, Rezaee A, Geinitz H et al (2016) Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-Fluorocholine PET\/CT. J Nucl Med 57(Suppl 3):55S\u2013560S","journal-title":"J Nucl Med"},{"key":"1412_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C et al (2017) PSMA Ligands for PET Imaging of Prostate Cancer. J Nucl Med 58:1452\u20131545","journal-title":"J Nucl Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01412-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T00:20:17Z","timestamp":1581207617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01412-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01412-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,9]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}